
PhoreMost advances brain cancer programme to trial
PhoreMost has announced a treatment for brain cancers as its lead programme, also appointing Dr Gabriel Fox as Chief Medical Officer. The biotechnology company will progress PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers, towards Phase I clinical trial. PMC-001 is… Read More















